Using genetics to explore whether the cholesterol-lowering drug ezetimibe may cause an increased risk of cancer | Zendy

Bo Kobberø Lauridsen | Zendy; Stefan Stender | Zendy; Ruth FrikkeSchmidt | Zendy; Børge G. Nordestgaard | Zendy; Anne TybjærgHansen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Using genetics to explore whether the cholesterol-lowering drug ezetimibe may cause an increased risk of cancer

Author(s) -

Bo Kobberø Lauridsen,

Stefan Stender,

Ruth FrikkeSchmidt,

Børge G. Nordestgaard,

Anne TybjærgHansen

Publication year - 2017

Publication title -

international journal of epidemiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.406

H-Index - 208

eISSN - 1464-3685

pISSN - 0300-5771

DOI - 10.1093/ije/dyx096

Subject(s) - ezetimibe , medicine , cancer , allele , population , hazard ratio , cholesterol , confidence interval , oncology , relative risk , pharmacology , bioinformatics , genetics , biology , environmental health , gene

Results from randomized controlled trials (RCTs) have raised concern that the cholesterol-lowering drug ezetimibe might increase the risk of cancer. We tested the hypothesis that genetic variation in NPC1L1, mimicking treatment with ezetimibe, was associated with an increased risk of cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research